Carolus Therapeutics, Inc. is a biopharmaceutical company committed to the development of innovative new drugs that will provide relief to patients suffering from a host of disorders triggered by acute and chronic inflammation. The clinical and commercialization focus of the company is on novel therapeutic strategies to noninvasively impede leukocyte recruitment at sites of inflammation by disrupting chemokine interactions and pro-inflammatory cytokines. The company’s patented technology represents a promising advance in inflammation therapy where the underlying disease, as opposed to the symptoms, is treated without significant side effect profiles.
Technology
Carolus’ technology and intellectual property has enabled modality-independent development of therapeutic peptides and antibodies that target specific interactions between MIF and its chemokine receptors, and RANTES and platelet factor-4.
News
Carolus Therapeutics, Inc. will present at the BioPartnering Europe conference on Monday, October 12, 2009 at 10:45 a.m. local time. The conference is being held at the QEII Conference Centre in London, United Kingdom. Court Turner, President, Chief Executive Officer and Director will provide an overview of Carolus Therapeutics, Inc., including an update on the preclinical development status of the company¹s lead program, CT-2008, and its MIF discovery program.